The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients

The variability in the clinical phenotype of Parkinson's disease seems to suggest the existence of several subtypes of the disease. To test this hypothesis we performed a cluster analysis using data assessing both motor and non-motor symptoms in a large cohort of newly diagnosed untreated PD pa...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 8; p. e70244
Main Authors Erro, Roberto, Vitale, Carmine, Amboni, Marianna, Picillo, Marina, Moccia, Marcello, Longo, Katia, Santangelo, Gabriella, De Rosa, Anna, Allocca, Roberto, Giordano, Flavio, Orefice, Giuseppe, De Michele, Giuseppe, Santoro, Lucio, Pellecchia, Maria Teresa, Barone, Paolo
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.08.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0070244

Cover

More Information
Summary:The variability in the clinical phenotype of Parkinson's disease seems to suggest the existence of several subtypes of the disease. To test this hypothesis we performed a cluster analysis using data assessing both motor and non-motor symptoms in a large cohort of newly diagnosed untreated PD patients. We collected data on demographic, motor, and the whole complex of non-motor symptoms from 100 consecutive newly diagnosed untreated outpatients. Statistical cluster analysis allowed the identification of different subgroups, which have been subsequently explored. The data driven approach identified four distinct groups of patients, we have labeled: 1) Benign Pure Motor; 2) Benign mixed Motor-Non-Motor; 3) Non-Motor Dominant; and 4) Motor Dominant. Our results confirmed the existence of different subgroups of early PD patients. Cluster analysis revealed the presence of distinct subtypes of patients profiled according to the relevance of both motor and non-motor symptoms. Identification of such subtypes may have important implications for generating pathogenetic hypotheses and therapeutic strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceived and designed the experiments: RE CV PB. Performed the experiments: RE CV MA MP KL GS MM RA FG GDM ADR LS GO MTP. Analyzed the data: RE CV. Wrote the paper: RE CV PB.
Competing Interests: Dr. Carmine Vitale has received honoraria for symposia from Boehringer Ingelheim, Lundbeck, Novartis, Schwarz Pharma/UCB, GSK. Dr. Gabriella Santangelo has received honoraria for symposia from Lundbeck. Prof Paolo Barone has received honoraria as a Consultant & Advisory Board Memberships for Novartis, Schwarz Pharma/UCB, Merck-Serono, Eisai, Solvay, General Electric and Lundbeck. He has received research support from Boehringer Ingelheim, Novartis, Schwarz Pharma/UCB, Merck-Serono, Solvay, and Lundbeck. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0070244